A phase 1 trial of E7974 administered on day 1 of a 21‐day cycle in patients with advanced solid tumors

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer

• Publication date

  2012-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/cncr.27428PMID 22294459
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin

  2009influential reference
• A phase I trial of E7974 administered on days 1 and 15 of a 28-day cycle in patients with solid malignancies

  2007cited by this paper
• RECIST revisited: a review of validation studies on tumour assessment.

  2006cited by this paper
• Toxicity in elderly breast cancer patients treated by a taxane based chemotherapy as adjuvant or neoadjuvant therapy for primary breast cancer.

  2006cited by this paper
• Synthetic analogs of the marine natural product hemiasterlin: Optimization and discovery of E7974, a novel and potent antitumor agent

  2005cited by this paper
• Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.

  2002cited by this paper
• Conservation of the Class I -Tubulin Gene in Human Populations and Lack of Mutations in Lung Cancers and Paclitaxel-resistant Ovarian Cancers 1

  2002cited by this paper
• Regulation of microtubule stability and mitotic progression by survivin.

  2002cited by this paper
• Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers.

  2002cited by this paper
• Effect of p53 Status on Tumor Response to Antiangiogenic Therapy

  2002cited by this paper
• Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance

  2001cited by this paper
• RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage

  2001cited by this paper
• Deoxycholate induces DNA damage and apoptosis in human colon epithelial cells expressing either mutant or wild-type p53.

  2001cited by this paper
• New drug development in the United States from 1963 to 1999

  2001cited by this paper
• Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.

  2001cited by this paper
• Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients

  2001cited by this paper
• Risks in new drug development: Approval success rates for investigational drugs

  2001cited by this paper
• Randomized Designs for Early Trials of New Cancer Treatments—An Overview

  2000cited by this paper
• Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1.

  2000cited by this paper
• Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.

  2000cited by this paper
• Measurement of the ADP:ATP ratio in human leukaemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis.

  2000cited by this paper
• Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors.

  1999cited by this paper
• Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model.

  1999cited by this paper
• Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.

  1999cited by this paper
• Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.

  1999cited by this paper
• Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina spp. sponges.

  1999cited by this paper
• Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

  1999cited by this paper
• Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.

  1999cited by this paper
• Caspases: enemies within.

  1998cited by this paper
• Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

  1998cited by this paper
• Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization*

  1997cited by this paper
• Multidrug-resistant Human Sarcoma Cells with a Mutant P-Glycoprotein, Altered Phenotype, and Resistance to Cyclosporins*

  1997cited by this paper
• Caspases: Intracellular Minireview Signaling by Proteolysis

  1997cited by this paper
• A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.

  1996cited by this paper
• Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation

  1996cited by this paper
• Cytotoxic peptides from the marine sponge Cymbastela sp.

  1995cited by this paper
• Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer.

  1994cited by this paper
• The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity.

  1993cited by this paper
• New drug development in the United States from 1963 to 1990

  1991cited by this paper
• A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry.

  1991cited by this paper
• Phase I and pharmacological study of vinblastine by prolonged continuous infusion.

  1986cited by this paper
• Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs.

  1983cited by this paper

• Peptides from Marine-Derived Fungi: Chemistry and Biological Activities

  2023cites this paper
• Immunoconjugates as immune canoes to kill breast cancer cells

  2021cites this paper
• Exploring the Diversity of the Marine Environment for New Anti-cancer Compounds

  2021cites this paper
• Antimicrobial Peptides Derived from Ascidians and Associated Cyanobacteria

  2021cites this paper
• Anti-tumour drugs of marine origin currently at various stages of clinical trials (review)

  2021cites this paper
• Bioactive peptides derived from marine sources: Biological and functional properties

  2021cites this paper
• Anticancer Potential of Compounds from the Brazilian Blue Amazon

  2020cites this paper
• Marine Invertebrate Natural Products that Target Microtubules.

  2018cites this paper
• Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides

  2018cites this paper
• Peptides, Peptidomimetics, and Polypeptides from Marine Sources: A Wealth of Natural Sources for Pharmaceutical Applications

  2017cites this paper
• Total Synthesis of the Marine Natural Product Hemiasterlin by Organocatalyzed α-Hydrazination.

  2017cites this paper
• Aspersymmetide A, a New Centrosymmetric Cyclohexapeptide from the Marine-Derived Fungus Aspergillus versicolor

  2017cites this paper
• Marine Sponge Natural Products with Anticancer Potential: An Updated Review

  2017cites this paper
• An overview of the marine natural products in clinical trials and on the market

  2015cites this paper
• The Travails of Clinical Trials with Marine-­Sourced Compounds

  2015cites this paper
• Complementary isonitrile-based multicomponent reactions for the synthesis of diversified cytotoxic hemiasterlin analogues.

  2015cites this paper
• Potent Cytotoxic Peptides from the Australian Marine Sponge Pipestela candelabra

  2014cites this paper
• Anticancer Agents from Diverse Natural Sources

  2014cites this paper
• Natural product chemistry and anticancer drug discovery

  2014cites this paper
• Natural products as antimitotic agents.

  2014cites this paper
• Cytotoxic scalarane sesterterpenes from a Korean marine sponge Psammocinia sp.

  2013cites this paper
• Marine Peptides and Proteins with Cytotoxic and Antitumoral Properties

  2013cites this paper